Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Search

Page Path
HOME > Search
2 "Insob Hwang"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
COVID-19: Brief Communication
Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea
Yunhyung Kwon, Insob Hwang, Mijeong Ko, Hyungjun Kim, Seontae Kim, Soon-Young Seo, Enhi Cho, Yeon-Kyeng Lee
Epidemiol Health. 2023;45:e2023006.   Published online December 26, 2022
DOI: https://doi.org/10.4178/epih.e2023006
  • 4,879 View
  • 161 Download
  • 2 Crossref
AbstractAbstract AbstractSummary PDF
Abstract
OBJECTIVES
In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to a passive adverse event reporting system, was launched to quickly report unusual symptoms post-vaccination. This study compared the frequency of adverse events after COVID-19 vaccination based on the vaccine type and the type of 2-dose regimen (homologous or heterologous).
METHODS
Self-reported adverse events were collected through a text-message survey for 7 days after each vaccination. This study included 50,950 vaccine recipients who responded to the survey at least once. Informed consent to receive surveys via text was obtained from the vaccine recipients on the date of first vaccination.
RESULTS
The recipients of mRNA vaccines reported local and systemic reactions 1.6 times to 2.8 times more frequently after dose 2 than after dose 1 (p<0.001), whereas ChAdOx1-S recipients reported significantly fewer local and systemic reactions after dose 2 than after dose 1 (p<0.001). Local and systemic reactions were approximately 2 times and 4 times more frequent for heterologous vaccination than for BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S regimens, respectively. Young individuals, female, and those receiving heterologous vaccine regimens including ChAdOx1-S/BNT162b2 vaccines reported more adverse events than older participants, male, and those with homologous vaccine regimens.
CONCLUSIONS
Although a heterologous regimen, youth, and female sex were associated with a higher risk of adverse reactions after COVID-19 vaccination, no critical issues were noted. Active consideration of heterologous schedules based on the evidence of efficacy and safety appears desirable.
Summary
Korean summary
본 연구는 코로나19 백신 접종 후 7일 동안 문자 설문조사를 통해 50,950명이 자가 보고한 이상반응자료를 분석하였다. mRNA 백신 접종자는1회 접종 후보다 2회 접종 후 국소 이상반응 및 전신이상반응을 1.6~2.8배 더 자주 보고한 반면, ChAdOx1-S 백신 접종자는1회 접종 후 보다 2회 접종 후 이상반응을 더 적게 보고하였다. 동종 백신접종 보다 교차 접종의 경우 2-4배 더 많은 이상반응을 보고 하였다. COVID-19 백신 접종 후 교차접종, 젊은 연령, 여성의 경우 좀 더 많은 이상반응을 보고하였지만,중대한 문제는 보고되지 않았다.
Key Message
Self-reported adverse events were collected through a text-message survey from 50,950 recipients for 7 days after COVID-19 vaccination. The mRNA vaccine recipients reported local and systemic reactions 1.6 to 2.8 times more frequently after dose 2 than after dose 1, whereas ChAdOx1-S recipients reported significantly fewer local and systemic reactions after dose 2 than after dose 1. Local and systemic reactions were approximately 2 to 4 times more frequent for heterologous vaccination than for homologous regimens. Although a heterologous regimen, youth, and female were associated with a higher risk of adverse reac¬tions after COVID-19 vaccination, no critical issues were noted.

Citations

Citations to this article as recorded by  
  • Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa
    Azwidihwi Takalani, Michelle Robinson, Phumeza Jonas, Annie Bodenstein, Vuyelo Sambo, Barry Jacobson, Vernon Louw, Jessica Opie, Jonny Peter, Pradeep Rowji, Ishen Seocharan, Tarylee Reddy, Nonhlanhla Yende-Zuma, Kentse Khutho, Ian Sanne, Linda-Gail Bekker
    Vaccine.2024; 42(6): 1195.     CrossRef
  • A Nationwide Survey of mRNA COVID-19 Vaccinee’s Experiences on Adverse Events and Its Associated Factors
    Dongwon Yoon, Ha-Lim Jeon, Yunha Noh, Young June Choe, Seung-Ah Choe, Jaehun Jung, Ju-Young Shin
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
COVID-19: Brief Communication
Clinical severity according to the primary infection variant in patients with suspected SARS-CoV-2 reinfection in Korea
Myung-Jae Hwang, Insob Hwang, Chungmin Park, Hanul Park, Taejong Son, Jong-Hun Kim
Epidemiol Health. 2023;45:e2023007.   Published online December 21, 2022
DOI: https://doi.org/10.4178/epih.e2023007
  • 5,077 View
  • 214 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract AbstractSummary PDF
Abstract
OBJECTIVES
We aimed to evaluate the severity of suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection according to variants of concern in Gyeongsangbuk-do and Daegu, Korea.
METHODS
The database of coronavirus disease 2019 (COVID-19) cases reported from epidemiological investigations through the integrated system operated by the Korea Disease Control and Prevention Agency, from January 20, 2020 to May 7, 2022 was combined with data from the Health Insurance Review and Assessment Service system. The severity odds ratio (SOR) in secondary infection episodes compared with primary infection was estimated using a generalized linear model with a binomial distribution.
RESULTS
In all patients, the SOR of SARS-CoV-2 reinfection was 0.89 (95% confidence interval [CI], 0.82 to 0.95), and the severity was lower than in the first infection. Patients who had been vaccinated within 91 days showed a more attenuated SOR (0.85; 95% CI, 0.74 to 0.98). However, despite vaccination, in patients with both primary and secondary infections caused by the Omicron variant, the severity was reduced to a lesser extent than in patients primarily infected with other variants.
CONCLUSIONS
We could make efforts to relieve the severity of COVID-19 in vulnerable populations, in which death is more likely, by recommending booster vaccinations in case of a resurgence.
Summary
Korean summary
국내 COVID-19 확진자들의 중증도 증가 위험은 재감염(2차감염) 시 감소하였지만, 1차감염과 재감염 모두 오미크론론 변이가 우세하였던 시기인 경우에는 오히려 증가하였다. 특히 마지막 예방접종일로부터 91일 이상인 확진자들과 60세이상 인구에서는 중증도 증가 위험이 더 높았다. 우리는 COVID-19가 장기화됨에 따라 취약인구집단에 대해 추가 예방접종을 권고함으로써 재감염시 중증도가 증가하는 것을 예방해야 할 필요가 있다.
Key Message
As COVID-19 prolongs, there is a need to recommend booster vaccinations for vulnerable populations to prevent the potential for increased severity in the event of reinfection.

Citations

Citations to this article as recorded by  
  • Changes in the intrinsic severity of severe acute respiratory syndrome coronavirus 2 according to the emerging variant: a nationwide study from February 2020 to June 2022, including comparison with vaccinated populations
    Boyeong Ryu, Eunjeong Shin, Dong Hwi Kim, HyunJu Lee, So Young Choi, Seong-Sun Kim, Il-Hwan Kim, Eun-Jin Kim, Sangwon Lee, Jaehyun Jeon, Donghyok Kwon, Sungil Cho
    BMC Infectious Diseases.2024;[Epub]     CrossRef
  • The effect of shortening the quarantine period and lifting the indoor mask mandate on the spread of COVID-19: a mathematical modeling approach
    Jung Eun Kim, Heejin Choi, Minji Lee, Chang Hyeong Lee
    Frontiers in Public Health.2023;[Epub]     CrossRef
  • Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2
    Magen E. Francis, Ethan B. Jansen, Anthony Yourkowski, Alaa Selim, Cynthia L. Swan, Brian K. MacPhee, Brittany Thivierge, Rachelle Buchanan, Kerry J. Lavender, Joseph Darbellay, Matthew B. Rogers, Jocelyne Lew, Volker Gerdts, Darryl Falzarano, Danuta M. S
    Nature Communications.2023;[Epub]     CrossRef
Epidemiol Health : Epidemiology and Health
© Korean Society of Epidemiology.